mice with depressive-like behavior, 3 suggesting central leptin resistance in the obese mice. Therefore, these evidences suggest that leptin-induced activation of BDNF in the central nervous system may be involved in cognition and synaptogenesis, while brain leptin resistance could contribute to obesity-related neurodegenerative diseases.
Ginseng, a traditional herbal medicine, is reported to be an adaptogen that enhances body stability against physical loads, and is also suggested to improve cognitive functions. 17 Extracts of ginseng promote neurite outgrowth of spinal cord neurons. 18 Ginsenoside Rb1 (Rb1) is one of the major bioactive saponins in ginseng. 18, 19 Recent animal and cell models show that Rb1 has neuroprotective 18, [20] [21] [22] and antiobesity effects. 23 For example, Rb1 increases BDNF expression in the forebrain of rats with cerebral ischemia. 20 In vitro, Rb1 reduces the neurotoxic effects of glutamate on neurite outgrowth in neurons. 18 Our previous study has demonstrated that Rb1 improves leptin signaling in the hypothalamus of obese mice. 24 The main aim of this study was to examine whether Rb1 can improve central leptin effects on BDNF expression and synaptogenesis in the prefrontal cortex during obesity using an in vivo and an in vitro model.
Firstly, we investigated the effect of Rb1 on leptin signaling in the prefrontal cortex of high-fat diet-induced obese mice. Furthermore, we investigated the effect of Rb1 on neurite outgrowth and synaptogenesis in cultured primary prefrontal cortical neurons in response to leptin and palmitic acid, one of the most abundant saturated fatty acids in human diet.
| MATERIALS AND METHODOLOGY

| Experimental animals and Rb1 treatment
Sixty C57Bl/6J male mice (6 weeks old, body weight: 19.6 ± 1.4 g)
were obtained from the Animal Resources Centre (Perth, WA, Australia), and housed in environmentally controlled conditions (temperature 22°C, 12 hour light/dark cycle). All mice were fed a lab chow diet (LC, 5% fat, Vella Stock Feeds, Doonside, NSW, Australia)
to acclimatize for 1 week. Throughout the study, LC was served as the low fat control diet and was provided ad libitum except where noted.
All procedures were approved by the Animal Ethics Committee, University of Wollongong, NSW, Australia, and complied with the
Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes. After acclimatization, the mice were fed a high-saturated fat diet (40% fat in calories) for 16 weeks and developed obesity (average body weight 44.2 ± 2.6 g). Subsequently, the obese mice were randomized into two groups and intraperitoneally (ip) administered 
| Intraperitoneal glucose tolerance test (IPGTT)
On day 18 of Rb1 treatment, the mice were fasted overnight and injected (ip) with glucose at a dose of 0.5 g/kg. Blood samples were taken from the tail vein, and blood glucose measured using a glucometer (Abbott Diabetes Care, Alameda, CA, USA) at 0 (fasting), 30, 60, and 120 minutes following glucose administration.
| Central leptin sensitivity test
After Rb1 treatment for 21 days, the mice were anesthetized by isoflurane inhalation and placed in a stereotactic device. The mice were implanted with an intracerebroventricular (icv) cannula into the right lateral brain ventricle (0.25 mm posterior and 1.0 mm lateral relative to Bregma and 2.5 mm inferior to the surface of the skull). 25 Five days after cannula implantation, the mice were fasted for 6 hours, and then administered with either leptin (0.1 μg/3 μL) or saline (3 μL) into the lateral ventricle through the cannula. Food intake was measured 1 and 4 hours after the leptin or vehicle injection. Body weight gain was recorded 24 hours after icv injection.
| Blood and tissue collection
Following a 4 day interval after measuring central leptin sensitivity, the mice were fasted for 6 hours, and were then given an icv injection of leptin or vehicle. The mice were sacrificed one hour after icv injection. Blood samples were collected in EDTA-coated tubes.
Plasma was collected after centrifugation at 845 g for 15 minutes.
Brain tissue was removed and immediately stored in liquid nitrogen.
Epididymal fat (left and right sides) was dissected, weighed, and immediately stored in liquid nitrogen. Plasma, brain, and epididymal fat samples were then transferred to a −80°C freezer until further analysis.
| Determination of plasma leptin and insulin
Plasma leptin and insulin were measured using the mouse metabolic magnetic bead panel kit (Merck Millipore, Billerica, MA, USA).
| Western blotting
Prefrontal cortical tissue, equivalent to the prelimbic cortex, was identified and dissected at the level of Bregma 2.8-1.98 mm according to a standard mouse brain atlas. 25 Tissue protein was extracted in an NP-40 lysis buffer as described in our previous study. 26 The antibodies were used as follows: pJAK2 (sc-21870) and BDNF (sc- 
| Immunofluorescence
For immunocytochemical staining, neurons were washed three times in phosphate-buffered saline (PBS), and then fixed with 4% paraformaldehyde (Sigma-Aldrich) for 30 minutes at room temperature. After rinsing with PBS, the neurons were permeabilized with 0.3% Triton-X (Sigma-Aldrich) in PBS (ie, PBST) for 10 minutes, and blocked with 5% 
| Neurite length and branching analysis
The quantification of neuronal morphology was carried out using the 
| RNA extraction and qRT-PCR
Total RNA was extracted from the cultured cells using Aurum total RNA mini kits (Bio-Rad Laboratories). Complementary DNA synthesis and quantitative real-time PCR (qPCR) were performed as previously described. 24 The primers used are listed in Table S2 . Amplification was carried out with 45 cycles of: 95°C for 10 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. The mRNA expression levels for MAP2, PSD95, SYN, and BDNF were normalized to γ-actin, which served as the internal control. Experiments were performed in triplicate.
F I G U R E 1 Chronic Rb1 prevented weight gain, fat deposition, and improved glucose tolerance in obese mice fed a high-saturated fat diet for 16 wk. Ginsenoside Rb1 (Rb1) treatment reduced average energy intake (A); prevented body weight gain (B) since day 9; reduced epididymal fat mass (C); as well as lowered blood glucose at time point 30 min and 60 min in the glucose tolerance test (D). LC, lab chow fed mice; Ob, high-saturated fat diet-induced obese mice without treatment; Ob + Rb1, high-saturated fat diet-induced obese mice chronic treated with ginsenoside Rb1. Data are presented as mean ± SEM (n = 6-8 
| RESULTS
| Ginsenoside Rb1 reduced energy intake, prevented weight gain, fat deposition, and improved glucose tolerance in obese mice
As shown in Figure 1A , high-saturated fat diet-induced obese mice showed higher average energy intake than LC lean mice, while Rb1 treatment decreased the average energy intake. Meanwhile, Rb1 treatment significantly reduced body weight gain in obese mice from day 9 to the end of the treatment ( Figure 1B ). Ginsenoside Rb1 (Rb1) also reduced the epididymal fat mass in obese mice, although it was still higher than LC mice ( Figure 1C ). In the IPGTT, the Rb1-treated group showed lower blood glucose at 30 and 60 minutes after glucose injection compared to the obese group without treatment ( Figure 1D ). However, at 0, 30, and 120 minutes, blood glucose in Rb1 group was still higher than the LC group.
| Ginsenoside Rb1 restored central leptin sensitivity and significantly reduced hyperleptinemia in obese mice
In the LC lean mice, leptin significantly reduced energy intake for 4 hours after the icv leptin injection (all P < 0.05, Table S3 ).
However, in the obese mice, the central leptin injection failed to suppress energy intake (all P > 0.05). Importantly, in the Rb1 treatment group, leptin significantly decreased food intake for 4 hours Plasma leptin was significantly higher in the obese mice compared with the LC mice (Table S3 ). Ginsenoside Rb1 (Rb1) treatment lowered plasma leptin in the obese mice (Ob/saline: 16.9 ± 2.0 ng/mL, (Ob + Rb1)/saline: 8.9 ± 1.1 ng/mL, P < 0.05), but icv leptin injection did not further decrease plasma leptin. increased by 81% in response to leptin compared with the saline injection, suggesting that Rb1 improved leptin-pJAK2-pSTAT3 signaling in the obese mice. We also determined the leptin-stimulated expression of BDNF in the prefrontal cortex. Results showed that in the LC group, leptin significantly increased BDNF expression in the prefrontal cortex by +41% ( Figure 2C ), but not in the obese mice. Chronic Rb1 treatment not only increased BDNF expression in the prefrontal cortex, but also facilitated leptin's action in increasing BDNF expression (P < 0.05).
| Ginsenoside
| Ginsenoside Rb1 increased leptin-induced BDNF expression in the prefrontal cortical neurons
Using cultured primary prefrontal cortical neurons, the effect of Rb1 on the leptin-stimulated BDNF expression under the circumstance of saturated fatty acid, palmitic acid exposure was examined. Leptin treatment significantly increased BNDF immunoreactivity by 65% (P < 0.001, Figure 3A ,B). However, in neurons pretreated with palmitic acid, leptin failed to increase BDNF immunoreactivity (P > 0.05).
Importantly, with Rb1 treatment, leptin increased BDNF immunoreactivity by 40% (P = 0.020) in palmitic acid pretreated neurons, suggesting that Rb1 is able to prevent palmitic acid-induced leptin insensitivity. Consistent with the immunocytochemistry, a similar pattern of BDNF mRNA expression was observed ( Figure 3C ).
| Palmitic acid reduced leptin-stimulated neurite outgrowth in the prefrontal cortical neurons, which can be reversed by Rb1 treatment
Following examination of BDNF, we examined neurite outgrowth, including neurite branching and length, in cultured primary cortical neurons (Figure 4 ). Leptin treatment significantly increased neurite branching (branches per neurite: +77%, P < 0.001, Figure 4D ; branches per cell: +80%, P < 0.001, Figure 4E ) compared to the saline treatment in cortical neurons. However, palmitic acid pretreatment significantly suppressed leptin-stimulated branching. Ginsenoside Rb1 (Rb1) significantly ameliorated palmitic acid-induced impairment in leptin-stimulated branching compared with the palmitic acid pretreatment (branches per neurite: +45%, P = 0.018, Figure 4D ; branches per cell: +56%, P = 0.001, Figure 4E ).
Ginsenoside Rb1 (Rb1) significantly reversed the palmitic acidinduced decrease in average neurite length and total neurite length per cell (P = 0.009 and P = 0.045, respectively, Figure 4G ,H). Firstly, leptin significantly increased average neurite length and total neurite length per cell (both P < 0.001) compared to the saline control group. However, after exposing cortical neurons to palmitic acid, leptin did not increase the average neurite length nor the total neurite length per cell (both Figure 4I ).
| Palmitic acid reduced leptin-mediated synaptogenesis in the prefrontal cortical neurons, which can be reversed by Rb1 treatment
We examined the effect of Rb1, in the presence of palmitic acid, on the postsynaptic density marker 95 (PSD95) in response to leptin in cortical neurons ( Figure 5A ,B, and Table S4 ). Leptin significantly increased PSD95 immunoreactivity (P < 0.001 both in dendrite and soma, Scale bar = 100 μm. Data are presented as mean ± SEM. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001 Figure 5A ,B) and mRNA expression (P < 0.001, Table S4 ) compared to the saline group. However, palmitic acid pretreatment decreased the leptin-elevated PSD95 immunoreactivity (P < 0.001 both in dendrite and soma, Figure 5A ,B) and mRNA expression (P = 0.007, Table   S4 ). Importantly, Rb1 corrected the alteration of leptin-stimulated PSD95 immunoreactivity (dendrite: P = 0.006; and soma: P < 0.001, Figure 5A ,B) and mRNA expression (+26%, P = 0.009, Table S4 ) in the palmitic acid pretreated cortical neurons.
We also examined the effects of Rb1, in the presence of palmitic acid, on the presynaptic marker, SYN, in response to leptin in cortical neurons ( Figure 6A ,B, and Table S4 ). The palmitic acid pretreatment decreased the leptin-elevated SYN immunoreactivity in both dendrite and soma (both P < 0.001, Figure 6A ,B) and mRNA expression (P = 0.004, Table S4 ). The Rb1 treatment ameliorated palmitic acidinduced impairment on leptin-stimulated SYN immunoreactivity in the dendrite (+55%, P = 0.011), but not in the soma (P > 0.05) of cortical neurons ( Figure 6A ,B).
| DISCUSSION
This study showed that Rb1 can reverse the adverse effects of high- In the present study, we found that leptin activates JAK2-STAT3 signaling in the prefrontal cortex in LC lean mice. The prefrontal cortex is important for cognitive control, 31 and high-fat diet reduces synaptic plasticity in this region 32 leading to learning and memory impairments. 33 Furthermore, in the present study, we found that leptin-JAK2-STAT3 signaling was substantially impaired in the prefrontal cortex of the obese mice. In obese individuals, central leptin insensitivity also exists. The prevalence of dementia and other neurodegenerative diseases was higher in obese subjects with hyperleptinemia, [34] [35] [36] which suggests that high plasma leptin levels unlikely activate signaling pathways in the brain of obese individuals. Therefore, central leptin resistance is a pathology of obesity. 37 Importantly, in the present study, Rb1 treatment improved impairments of the leptin-pJAK2-pSTAT3 signaling pathway in the prefrontal cortex, restored central leptin sensitivity and reduced hyperleptinemia in obese mice. Previously, both clinical and animal studies have shown that ginseng extract or Rb1 treatment improves cognitive function. 17, [38] [39] [40] Therefore, these findings, including ours, suggest that Rb1, in improving the leptin-JAK2-STAT3 pathway in the prefrontal cortex, may contribute to ginseng and Rb1 in improving cognition. In this study, we demonstrated the beneficial effect of leptin on neurite outgrowth and synaptogenesis in cultured primary prefrontal cortical neurons. We found leptin increases neurite branching and length, neurite marker MAP2 mRNA expression, and synaptic marker (PSD95 and SYN) immunoreactivity and mRNA expression. It has been reported that the expression of synaptogenesis markers, SYN and PSD95, depends on BDNF processing. 44, 45 It is known that leptin signaling molecules, JAK2 and STAT3, distribute around the postsynaptic sites in the cerebral cortex. 46 Therefore, leptin may promote neurogenesis and synaptic plasticity via activation of leptin signaling molecules and increasing BDNF, SYN, and PSD95 in cortical neurons.
Furthermore, we found that high-saturated fatty acid diet impaired leptin signaling JAK2 and STAT3 in the prefrontal cortex. We confirmed that saturated palmitic acid impaired leptin's action on neurite outgrowth and synaptogenesis in cultured prefrontal cortical neurons. 4L oil) . B, Quantification of SYN immunoreactivity: mean intensity of SYN fluorescence in dendrite and soma of cortical neurons were measured using Image J Software. A total of 6-7 images per group and 7-8 neurons per image, as well as 2-4 dendrites per neuron were applied to the analysis. Data are presented as mean ± SEM (n = 6-7, ie, 6-7 images per group obtained from three independent experiments). *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001 the plasma membrane replacing membrane cholesterol, which increases membrane fluidity and changes the immediate environment of cell membrane proteins, such as the GABA receptor. 47, 48 Furthermore, ginsenoside may traverse cell membranes freely and activate intracellular membrane receptors, such as steroid receptors, which may regulate the transcription of target genes. 47 This study demonstrated that Rb1 increased leptin sensitivity in the prefrontal cortex of obese mice, and in prefrontal cortical neurons treated with palmitic acid, as well as reversed the alterations of leptin downstream signaling molecules (pJAK2, STAT3, BDNF, and PSD95). However, it remains to be determined if Rb1 directly interacts with the leptin receptor. Furthermore, it is reported that hyperleptinemia is required for the development of leptin resistance in diet-induced obese mice. 49 In our study, Rb1 significantly attenuates hyperleptinemia in obese mice, which may reduce the overstimulation of the leptin receptor, thereby improving downstream signaling.
In summary, this study has shown ginsenoside Rb1 treatment ameliorates alteration of leptin-pJAK2-pSTAT3 and leptin-BDNF in the prefrontal cortex of obese mice and improves hyperleptinemia.
Treatment with Rb1 also promoted leptin's effect on neurite branching and elongation, and synaptogenesis in prefrontal cortical neurons. As high-fat diet-induced obesity has been implicated in the progression of neurodegenerative diseases, such as vascular dementia, Rb1 treatment may have therapeutic effects in attenuating the progression of cognitive decline in obese patients and reducing the risk of neurodegenerative diseases. This will be the next work to further validate using obese mice model.
